Down 5% on Nov 2, and still 4% under its Oct 30 close.
−3Long-term trend
Follow CRMD's trial news. Pro members can get an alert when CorMedix files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Since its 2025 high | Down 67% |
| Latest filing | 8-K, Nov 9 |
ReportReports Thursday, before the open. Every 3 months, a company tells everyone how much it sold and earned. It rose after 2 and fell after 2 of its last 4 reports, +0.9% on average. Past reports ›
After its last 4 reports it closed +0.9% on average, higher 2 of 4 times.
Director Janet Dillione sold 10,000 shares on Jan 21, under a planned sale.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
CRMD is #53 of 90 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 53 |
Reports Thu Nov 12, before the open (in 2 days). Confirmed.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
CRMD's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| Total revenue | $325M to $345M |
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 2, 2026 | +0.1% | -5.4% | -6.6% |
| Aug 13, 2026 | +18.2% | +14.7% | +20.0% |
| May 14, 2026 | +13.9% | +5.7% | +5.7% |
Sales grew in two of the last six years, to $312M in 2025. It turned a profit in 2025 after a loss in 2024.
RSI 29.4, MACD below signal, below both averages. Not scored.
Officers and directors with a Form 4 in the last 12 months.
In ETFs: CRMD is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
“The drug and medical device industries are highly competitive and subject to rapid and significant technological change.”
CRMD scores 1 today, which Breakaway calls Below Average. It is #53 of 90 in Pharma by Quality Score, with 3 of 14 chart checks firing. Down 5% on Nov 2, and still 4% under its Oct 30 close. Shares: 15.5% more than a year ago (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
CRMD scores 1 today, which Breakaway calls Below Average (0 to 5). That is #53 of 90 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind CRMD's 1.
Reports Thu Nov 12, before the open, a date the company confirmed. CRMD closed higher after 2 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free for 24 hours. No account. No card. Then keep going with a free account.